… These properties of DCs can be harnessed for the benefit of tumour immunotherapy through
several means. One strategy is to target the cell-surface molecules of DCs with antibodies. …

… of cancer immunotherapy. It is important to remember that passive immunotherapy with
monoclonal antibodies is now a considerable success with great hopes for the future ( …

… To date, human tumor immunotherapy has met with only limited success. Amongthe reasons
for this have been the limited availability of tumor-associatedantigens and the inability to …

… cancer immunotherapy. Many strategies have been developed to target DCs in … in cancer
immunology and consider the therapeutic potential of targeting DCs in patients with cancer. …

… has been a major focus on the use of DC in cancer immunotherapy. DC have been used to
vaccinate … Cancer immunotherapy via dendritic cells Nat Rev Cancer, 12 (2012), pp. 265-277 …

… In the past decade, new developments in cancer treatment have been dominated by targeted
therapies using kinase inhibitors and monoclonal antibodies, which have become part of …

… and potent form of cancer immunotherapy and has clinically … The dendritic cells capture
and present antigens, and … to activation via dendritic cell signaling, T cells will elicit anti-tumor …

… A novel approach to vaccination against cancer is to exploit dendritic cells (DCs) as ‘nature’s
adjuvants’ and actively immunize cancer patients with a sample of their own DCs primed …

… These studies show that antigen-loaded dendritic cell vaccinations are safe and promising
in the treatment of cancer. This review discusses the use of dendritic cells in immunotherapy …

… Cancer immunotherapy aims at eliciting an immune response directed … tumor antigens
to help fight off residual tumor cells and thereby improve survival and quality of life of cancer …